Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  3,477 results for ""Capecitabine""

Your Filters

Subject : antineoplastic combined chemotherapy protocols
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Short-term outcomes of a phase II trial of perioperative capecitabine plus oxaliplatin therapy for advanced gastric cancer with extensive lymph node metastases (OGSG1701).

  • Authors : Kimura Y; Department of Surgery, Kindai Nara Hospital, 1248-1 Otoda-cho, Ikoma, Nara, 630-0293, Japan. .; Sugimoto N

Subjects: Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/drug therapy ; Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/pathology ; Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/surgery

  • Source: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association [Gastric Cancer] 2025 Jan; Vol. 28 (1), pp. 112-121. Date Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 100886238 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Phase II trial evaluating the long-term efficacy and peripheral sensory neuropathy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer.

  • Authors : Hata T; Department of Surgery, Japan Organization of Occupational Health and Safety, Kansai Rosai Hospital, 3-1-69 Inabaso, Amagasaki, Hyogo, 660-8511, Japan. .; Uemura M

Subjects: Capecitabine*/Capecitabine*/Capecitabine*/administration & dosage ; Capecitabine*/Capecitabine*/Capecitabine*/adverse effects ; Capecitabine*/Capecitabine*/Capecitabine*/therapeutic use XELOX

  • Source: Scientific reports [Sci Rep] 2024 Nov 02; Vol. 14 (1), pp. 26434. Date of Electronic Publication: 2024 Nov 02.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Alternating Oxaliplatin and Irinotecan Chemotherapy Combined With Capecitabine and Bevacizumab for Microsatellite-stable Stage IV Metastatic Colon Cancer With a BRAF V600E Mutation: Two Case Reports Indicating Survival Improvement over Standard Therapy.

  • Authors : Zhang Y; Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, P.R. China.; Li X

Subjects: Bevacizumab*/Bevacizumab*/Bevacizumab*/administration & dosage ; Bevacizumab*/Bevacizumab*/Bevacizumab*/therapeutic use ; Capecitabine*/Capecitabine*/Capecitabine*/administration & dosage

  • Source: Anticancer research [Anticancer Res] 2025 Jan; Vol. 45 (1), pp. 399-404.Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model: Print Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer.

  • Authors : File DM; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC.; Abdou Y

Subjects: Capecitabine*/Capecitabine*/Capecitabine*/administration & dosage ; Capecitabine*/Capecitabine*/Capecitabine*/adverse effects ; Capecitabine*/Capecitabine*/Capecitabine*/therapeutic use

  • Source: Clinical breast cancer [Clin Breast Cancer] 2024 Dec; Vol. 24 (8), pp. 683-690. Date of Electronic Publication: 2024 Aug 08.Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Distinctive grade based on Ki67 index and immune microenvironment of metastatic pancreatic neuroendocrine tumors responding to capecitabine plus temozolomide.

  • Authors : Gao H; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.

Subjects: Temozolomide*/Temozolomide*/Temozolomide*/therapeutic use ; Temozolomide*/Temozolomide*/Temozolomide*/pharmacology ; Temozolomide*/Temozolomide*/Temozolomide*/administration & dosage

  • Source: BMC cancer [BMC Cancer] 2024 Nov 07; Vol. 24 (1), pp. 1362. Date of Electronic Publication: 2024 Nov 07.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403).

  • Authors : Sugimoto N; Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan; .

Subjects: Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/drug therapy ; Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/pathology ; Capecitabine*/Capecitabine*/Capecitabine*/administration & dosage XELOX

  • Source: Anticancer research [Anticancer Res] 2025 Jan; Vol. 45 (1), pp. 307-313.Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model: Print Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

A pathological complete response to capecitabine plus oxaliplatin regimen combined with tislelizumab in advanced gastric cancer with liver metastases: A case report.

  • Authors : Sheng LP; Department of Gastroenterology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.; Huang YL

Subjects: Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/drug therapy ; Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/pathology ; Capecitabine*/Capecitabine*/Capecitabine*/administration & dosage

  • Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2024 Dec 31; Vol. 20 (1), pp. 2406061. Date of Electronic Publication: 2024 Oct 14.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study.

  • Authors : Jing C; Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China.; Bai Z

Subjects: Capecitabine*/Capecitabine*/Capecitabine*/therapeutic use ; Capecitabine*/Capecitabine*/Capecitabine*/adverse effects ; Capecitabine*/Capecitabine*/Capecitabine*/administration & dosage

  • Source: The oncologist [Oncologist] 2024 Nov 04; Vol. 29 (11), pp. e1565-e1574.Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Gemcitabine, capecitabine, and tislelizumab in recurrent/metastatic nasopharyngeal carcinoma following prior anti-PD-1 therapy failure: A retrospective study.

  • Authors : Yang R; Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, China.; Li R

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/administration & dosage ; Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/analogs & derivatives

  • Source: Oral oncology [Oral Oncol] 2024 Nov; Vol. 158, pp. 106981. Date of Electronic Publication: 2024 Aug 13.Publisher: Elsevier Country of Publication: England NLM ID: 9709118 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0593

Record details

Read More Add to Saved list
×
Academic Journal

Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer.

  • Authors : Qiu MZ; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, PR China. .; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, PR China. .

Subjects: Capecitabine*/Capecitabine*/Capecitabine*/administration & dosage ; Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/drug therapy ; Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/pathology XELOX

  • Source: Signal transduction and targeted therapy [Signal Transduct Target Ther] 2024 Dec 16; Vol. 9 (1), pp. 349. Date of Electronic Publication: 2024 Dec 16.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101676423 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  3,477 results for ""Capecitabine""